The search for better prognostic models in myelodysplastic syndromes

Current Hematologic Malignancy Reports

Volumn 6, Issue 1, 2011, Pages 13-21

  Santos, Fabio P S ^b   Kantarjian, Hagop ^a   Garcia Manero, Guillermo ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

IPSS; MDS; Myelodysplastic syndrome; Prognosis; WPSS

Indexed keywords

DNA;

AGE DISTRIBUTION; ARTICLE; BONE MARROW; CYTOGENETICS; CYTOPENIA; DNA METHYLATION; ERYTHROCYTE TRANSFUSION; GENE MUTATION; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; KARYOTYPE; MORPHOLOGY; MYELODYSPLASTIC SYNDROME; PROGNOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

HUMANS; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RISK FACTORS;

EID: 79551478889     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-010-0070-x     Document Type: Article

References (50)

1. A Tefferi JW Vardiman 2009 Myelodysplastic syndromes N Engl J Med 361 1872 85 1:CAS:528:DC%2BD1MXhtl2jurvJ 10.1056/NEJMra0902908 19890130
2. MA Sekeres WM Schoonen H Kantarjian, et al. 2008 Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys J Natl Cancer Inst 100 1542 51 10.1093/jnci/djn349 18957672
3. DE Rollison N Howlader MT Smith, et al. 2008 Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs Blood 112 45 52 1:CAS:528:DC%2BD1cXotlymu7Y%3D 10.1182/blood-2008-01-134858 18443215
4. BP Alter N Giri SA Savage, et al. 2010 Malignancies and survival patterns in the National Cancer Institute inherited bone marrow failure syndromes cohort study Br J Haematol 150 179 88 20507306
5. SM Smith MM Le Beau D Huo, et al. 2003 Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series Blood 102 43 52 1:CAS:528:DC%2BD3sXltFemtLg%3D 10.1182/blood-2002-11-3343 12623843 (Pubitemid 36759634)
6. P Valent HP Horny JM Bennett, et al. 2007 Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference Leuk Res 31 727 36 10.1016/j.leukres.2006.11.009 17257673 (Pubitemid 46855901)
7. JM Bennett D Catovsky MT Daniel, et al. 1982 Proposals for the classification of the myelodysplastic syndromes Br J Haematol 51 189 99 1:STN:280:DyaL383gs1GhtQ%3D%3D 6952920
8. GJ Mufti JR Stevens DG Oscier, et al. 1985 Myelodysplastic syndromes: a scoring system with prognostic significance Br J Haematol 59 425 33 1:STN:280:DyaL2M7it1GmsQ%3D%3D 10.1111/j.1365-2141.1985.tb07329.x 3970861
9. GF Sanz MA Sanz T Vallespi, et al. 1989 Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients Blood 74 395 408 1:STN:280:DyaL1MzitleltQ%3D%3D 2752119
10. P Greenberg C Cox MM LeBeau, et al. 1997 International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079 88 1:CAS:528:DyaK2sXhvVars70%3D 9058730
11. L Malcovati U Germing A Kuendgen, et al. 2007 Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes J Clin Oncol 25 3503 10 10.1200/JCO.2006.08.5696 17687155 (Pubitemid 47315575)
12. H Kantarjian S O'Brien F Ravandi, et al. 2008 Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System Cancer 113 1351 61 1:CAS:528:DC%2BD1cXhtFyls7rM 10.1002/cncr.23697 18618511 This study of a large group of patients with MDS defines a prognostic scoring system that includes patients with prior therapy, secondary MDS, and CMML with leukocytosis
13. P Fenaux GJ Mufti E Hellstrom-Lindberg, et al. 2009 Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 223 32 1:CAS:528:DC%2BD1MXisFWjsbc%3D 10.1016/S1470- 2045(09)70003-8 19230772
14. H Kantarjian JP Issa CS Rosenfeld, et al. 2006 Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study Cancer 106 1794 803 1:CAS:528:DC%2BD28XksFCrsrk%3D 10.1002/cncr.21792 16532500
15. A Aribi G Borthakur F Ravandi, et al. 2007 Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia Cancer 109 713 7 1:CAS:528:DC%2BD2sXis1Smt70%3D 10.1002/cncr.22457 17219444 (Pubitemid 46233232)
16. Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001.
17. S Rosati R Mick F Xu, et al. 1996 Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome Leukemia 10 20 6 1:STN:280:DyaK287ksFajtw%3D%3D 8558932
18. A Matsuda I Jinnai F Yagasaki, et al. 1998 Refractory anemia with severe dysplasia: clinical significance of morphological features in refractory anemia Leukemia 12 482 5 1:STN:280:DyaK1c3hs1KrsA%3D%3D 10.1038/sj.leu.2400966 9557604 (Pubitemid 28197570)
19. SM Dunkley A Manoharan YL Kwan 2002 Myelodysplastic syndromes: prognostic significance of multilineage dysplasia in patients with refractory anemia or refractory anemia with ringed sideroblasts Blood 99 3870 1 1:CAS:528: DC%2BD38XjvVGms7w%3D 10.1182/blood-2001-11-0120 12014369 author reply 1 (Pubitemid 34534569)
20. L Malcovati MG Porta C Pascutto, et al. 2005 Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making J Clin Oncol 23 7594 603 10.1200/JCO.2005.01. 7038 16186598 (Pubitemid 46291823)
21. MG Della Porta L Malcovati E Boveri, et al. 2009 Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes J Clin Oncol 27 754 62 10.1200/JCO.2008.18.2246 19103730
22. A Oriani C Annaloro D Soligo, et al. 1996 Bone marrow histology and CD34 immunostaining in the prognostic evaluation of primary myelodysplastic syndromes Br J Haematol 92 360 4 1:STN:280:DyaK287ovFyntQ%3D%3D 10.1046/j.1365-2141.1996. d01-1484.x 8603000
23. G Tricot C De Wolf-Peeters R Vlietinck RL Verwilghen 1984 Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS Br J Haematol 58 217 25 1:STN:280:DyaL2M%2FgtVehtw%3D%3D 10.1111/j.1365-2141.1984.tb06079.x 6477833
24. G Buesche H Teoman W Wilczak, et al. 2008 Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes Leukemia 22 313 22 1:CAS:528:DC%2BD1cXhvVyltL4%3D 10.1038/sj.leu.2405030 18033321 (Pubitemid 351265130)
25. D Haase U Germing J Schanz, et al. 2007 New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients Blood 110 4385 95 1:CAS:528:DC%2BD1cXot1Sq 10.1182/blood-2007-03-082404 17726160 (Pubitemid 351377805)
26. Schanz J, Tuechler H, Sole F, et al. Cytogenetic risk features in MDS-Update and present state [abstract]. Blood 2009, 114:Abstract 2772.
27. Schanz J, Estey EH, Steidl C, et al. Multivariate analysis suggests that the prognostic impact of poor cytogenetics is potentially underestimated in the IPSS [abstract]. Blood 2007, 110:Abstract 248.
28. LP Gondek R Tiu CL O'Keefe, et al. 2008 Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML Blood 111 1534 42 1:CAS:528:DC%2BD1cXhvFeju78%3D 10.1182/blood-2007-05-092304 17954704 (Pubitemid 351213443)
29. Sanz G, Nomdedeu B, Such E, et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Blood 2008, 112:Abstract 640.
30. Della Porta MG, Malcovati L, Travaglino E, et al. a prognostic model for predicting the impact of comorbidities on survival of patients with myelodysplastic syndromes [abstract]. Blood 2007, 110:Abstract 2453.
31. AA Di Tucci G Matta S Deplano, et al. 2008 Myocardial iron overload assessment by T2*magnetic resonance imaging in adult transfusion dependent patients with acquired anemias Haematologica 93 1385 8 10.3324/haematol.12759 18603557
32. Mattiuzzi G, Amin HM, Kantarjian H, et al. Baseline serum ferritin predicts rate of infection in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome [abstract]. Blood 2009, 114:Abstract 1611.
33. Leitch HA, Wong DHC, Leger CS, et al. Improved leukemia-free and overall survival in patients with myelodysplastic syndrome receiving iron chelation therapy: a subgroup analysis [abstract]. Blood 2007, 110:Abstract 1469.
34. ML Sorror MB Maris R Storb, et al. 2005 Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT Blood 106 2912 9 1:CAS:528:DC%2BD2MXhtFantbfL 10.1182/blood-2005-05-2004 15994282 (Pubitemid 41510773)
35. R Wang CP Gross S Halene X Ma 2009 Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes Leuk Res 33 1594 8 10.1016/j.leukres.2009.02.005 19324411
36. WR Sperr F Wimazal M Kundi, et al. 2010 Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group Ann Oncol 21 114 9 1:STN:280:DC%2BD1Mfisl2itg%3D%3D 10.1093/annonc/mdp258 19605505
37. E Zipperer D Pelz K Nachtkamp, et al. 2009 The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome Haematologica 94 729 32 10.3324/haematol.2008.002063 19336740
38. H Harada Y Harada H Niimi, et al. 2004 High incidence of somatic mutations in the AML1/RUNX1 gene in myelodysplastic syndrome and low blast percentage myeloid leukemia with myelodysplasia Blood 103 2316 24 1:CAS:528:DC%2BD2cXitlCjsrY%3D 10.1182/blood-2003-09-3074 14615365 (Pubitemid 38326252)
39. Y Kita-Sasai S Horiike S Misawa, et al. 2001 International prognostic scoring system and TP53 mutations are independent prognostic indicators for patients with myelodysplastic syndrome Br J Haematol 115 309 12 1:CAS:528:DC%2BD3MXptVyqsrk%3D 10.1046/j.1365-2141.2001.03073.x 11703325 (Pubitemid 34203492)
40. H Kaneko S Misawa S Horiike, et al. 1995 TP53 mutations emerge at early phase of myelodysplastic syndrome and are associated with complex chromosomal abnormalities Blood 85 2189 93 1:CAS:528:DyaK2MXltVSru7g%3D 7718890
41. O Kosmider V Gelsi-Boyer M Cheok, et al. 2009 TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs) Blood 114 3285 91 1:CAS:528:DC%2BD1MXhtlShtbnL 10.1182/blood-2009-04-215814 19666869
42. S Ito AC D'Alessio OV Taranova, et al. 2010 Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification Nature 466 1129 33 1:CAS:528:DC%2BC3cXovFCntro%3D 10.1038/nature09303 20639862
43. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010 Aug 6 (Epub ahead of print).
44. ME Figueroa L Skrabanek Y Li, et al. 2009 MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation Blood 114 3448 58 1:CAS:528:DC%2BD1MXhtlensb7E 10.1182/blood-2009-01-200519 19652201
45. L Shen H Kantarjian Y Guo, et al. 2010 DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes J Clin Oncol 28 605 13 1:CAS:528:DC%2BC3cXisVGgtbo%3D 10.1200/JCO.2009.23.4781 20038729 This important study examines the role of gene promoter CpG island methylation in patients with MDS treated with the hypomethylating agent decitabine and correlates it with the response and outcome
46. EP Alessandrino MG Della Porta A Bacigalupo, et al. 2008 WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) Blood 112 895 902 1:CAS:528:DC%2BD1cXpsVaisLs%3D 10.1182/blood-2008-03-143735 18497321
47. Hugo SE, Bundrick SC, Hanson CA, Steensma DP. Independent validation of the MD Anderson Cancer Center risk model for myelodysplastic syndromes (MDS), and comparison to the International Prognostic Scoring System (IPSS) and the World Health Organization-Based Prognostic Scoring System (WPSS) [abstract]. Blood 2009, 114:Abstract 3814.
48. G Garcia-Manero J Shan S Faderl, et al. 2008 A prognostic score for patients with lower risk myelodysplastic syndrome Leukemia 22 538 43 1:STN:280:DC%2BD1c7nsVKntw%3D%3D 10.1038/sj.leu.2405070 18079733 This study examines the potential prognostic factors for the outcome of patients with lower-risk disease (Pubitemid 351386723)
49. Kim H, Jabbour E, Kadia T, et al. A prognostic model of therapy-related myelodysplastic syndrome [abstract]. Blood 2009, 114:Abstract 3796.
50. Tong WG, Kadia T, Borthakur G, et al. Prognostic factors and survival in patients with hypocellular myelodysplastic syndrome: development of a disease specific prognostic score [abstract]. Blood 2009, 114:Abstract 3819.